Press release BoxID: 126342 (Speedel Pharma AG)
  • Speedel Pharma AG
  • Hirschgässlein 11
  • 4051 Basel
  • Contact person
  • Nick Miles
  • +41 (61) 20640-00

Speedel Announces Appointment to Management Team

New appointment adds significant drug discovery expertise

(PresseBox) (Basel, ) Speedel (SWX: SPPN) today announced a new appointment to its Management Team.

- Dr Klaus Dembowsky as Head of Speedel Experimenta, Speedel's late-stage research unit. He is a MD and PhD in physiology and has extensive experience in managing research laboratories in both Big Pharma and Biotech in Germany and the USA with Bayer, Millenium, and Ingenium Pharmaceuticals. Dr Dembowsky will also serve on Speedel's Management Team.

Dr Alice Huxley, CEO, commented: "I am delighted to welcome Dr Dembowsky as Head of Speedel Experimenta and to our Management Team. He brings a wealth of drug discovery and management expertise which is invaluable as Speedel looks forward to its next phase of organisational growth. For Speedel it is imperative to conduct top science in order to secure its clinical pipeline and deliver innovative drugs to patients."

Dr Klaus Dembowsky, stated: "It is a great challenge to have this opportunity of working with the team at Speedel Experimenta and with the Management Team, as it builds on its foundations as one of Europe's premier biopharmaceutical companies."

Biography of new appointment

Dr Klaus Dembowsky was born in 1953 and is a German citizen. He studied medicine at the Universities of Mainz and Heidelberg, Germany and received his doctorate from the University of Heidelberg. From 1982-1992 he held a number of positions in the Department of Physiology, University of Heidelberg. In 1992 he was appointed Head of Laboratory at Bayer AG, Institute of Cardiovascular Research, Wuppertal, Germany. From 2001 to 2003 he was Project Manager for the alliance between Bayer AG and Millenium in Cambridge, USA which focused on research in cardiovascular, thrombosis and haematology. Since 2003 Klaus Dembowsky has been Vice President Drug Discovery at Ingenium Pharmaceuticals AG, Martinsried, Germany. He has published extensively and is the holder of over 200 patent applications for novel compounds and targets.

The other members of the Management Team of Speedel Holding Ltd remain unchanged and further details are available on